New eye implant could slow vision loss in diabetes

NCT ID NCT07235085

Recruiting now Disease control Sponsor: Ocular Therapeutix, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tests an implant called OTX-TKI that slowly releases the drug axitinib inside the eye. It aims to stop or slow worsening of non-proliferative diabetic retinopathy, a common diabetes complication that can lead to vision loss. About 930 adults with moderate to severe disease will receive either one or two implants or a sham procedure. The main goal is to see if the implant improves retinal health after one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: axitinib implant (OTX-TKI)
What this could lead to: If it works, this could offer a long-lasting treatment to slow or stop vision loss from diabetic retinopathy, reducing the need for frequent eye injections.
What could go wrong: This is an early Phase 3 trial, so results are not yet proven. The implant may not improve vision for everyone, and there are risks like eye infection or inflammation from the injection procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-PROLIFERATIVE DIABETIC RETINOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

background diabetic retinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-PROLIFERATIVE DIABETIC RETINOPATHY

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cumberland Valley Retina Consultants
RECRUITING

Hagerstown, Maryland, 21740, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.